Former Cathay Fund Manager Jiang Ying, Who Posted Losses Across 3 Products During Tenure, Transitions to Board Secretary Role at Luoxin Pharmaceuticals; Previous Secretary Earned 840,000 Yuan Annually

Deep News
2025/10/14

Another case has emerged of a fund manager transitioning to become a board secretary at a listed company.

On October 13, Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) announced that board secretary Han Fengsheng resigned due to work transfer arrangements. The board of directors subsequently approved the appointment of Jiang Ying as the new board secretary. Notably, this new secretary does not come from a traditional corporate management background, but is a former fund manager with extensive experience in public fund management.

According to public records, Jiang Ying was born in October 1987 and holds dual bachelor's degrees in science and economics from Peking University, a master's degree in management from Peking University, and a master's degree in finance from the University of Hong Kong. Her career path has been comprehensive: she previously worked at Guojin Securities Asset Management subsidiary and Everbright Prudential Fund before joining Cathay Fund in March 2016, where she served as research analyst, assistant fund manager, and fund manager.

Jiang Ying officially began managing public fund products in December 2020 and served as a fund manager for four years, managing three fund products: Cathay Taurus Innovation Growth Mixed Fund (020010.OF), Cathay STAR Market Two-Year Regular Open Mixed Fund (506009.OF), and Cathay Small and Mid-Cap Growth Mixed Fund (160211.OF).

From a performance perspective, the returns of all three funds managed by Jiang Ying during her tenure were disappointing. During her management period, Cathay Taurus Innovation Growth posted a return of -7.01%, Cathay STAR Market Two-Year Regular Open returned -12.48%, and Cathay Small and Mid-Cap Growth returned -34.28%. Her peak management period occurred in the first quarter of 2022, when her total assets under management reached a maximum of 25.9 billion yuan. Subsequently, the scale gradually declined. Finally, on December 24, 2024, Jiang Ying officially stepped down from her last fund position, with Cathay Fund announcing the next day that the departure was due to "personal reasons."

According to the Luoxin Pharmaceuticals announcement, former board secretary Han Fengsheng received compensation of 845,700 yuan for 2024. Jiang Ying's future work performance and compensation package will be worth continued attention.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10